drugset / Trial / NCT00834873
Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects
RandomizedCrossoverOpen-labelOther
Summary
The objective of this randomized, single-dose, two-way crossover evaluation is to compare the relative bioequivalence of a test carvedilol formulation (TEVA Pharmaceuticals USA) to and equivalent oral dose of the commercially available carvedilol (COREG®, SmithKline Beecham Pharmaceuticals) in a test population of 24 adult individuals under fed conditions.
Timeline
- Start
- 2001-12
- Primary completion
- 2001-12
- Completion
- 2001-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carvedilol | Other / unclassified | 25 mg | Oral |
Indications
No indication recorded.